
    
      Assessment of the overall (OS); one year; two years and three years' survival rates; the
      disease free survival (DFS) and the tumor response rate in the patients undergoing (PAT or
      PEI) for the large and inoperable hepatocellular carcinoma. This is a prospective non
      randomized trial carried out at the Ribat University Hospital between May 2017 to April 2020.
    
  